 RANCHO CUCAMONGA, Calif., Dec. 29, 2020 GLOBE NEWSWIRE -- Amphastar Pharmaceuticals, Inc., NASDAQ: AMPH announced that the U.S. Food and Drug Administration FDA has approved its Abbreviated New Drug Application ANDA for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. Amphastars newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lillys Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA rDNA-origin. 